Table 2.
Histopathological and molecular characteristics.
| Characteristic* | N |
|---|---|
| Grade | |
| 1–2 | 28 (26.4%) |
| 3 | 78 (73.6%) |
| 3A | 64 (60.4%) |
| 3B | 9 (8.5%) |
| Unknown | 5 (4.7%) |
| Number of lymph node involvement | |
| 1–3 | 81 (76.4%) |
| ≥ 4 | 25 (23.6%) |
| Number of extra-nodal involvement | |
| 0 | 46 (43.4%) |
| 1–2 | 50 (47.2%) |
| 3–7 | 9 (42.3%) |
| Bone Marrow Involvement | |
| Negative | 73 (73.0%) |
| Positive | 27 (27.0%) |
| Serum LDH | |
| Not elevated | 35 (33.0%) |
| Elevated | 71 (67.0%) |
| DLBCL component | |
| < 50% | 29 (27.4%) |
| ≥ 50% | 69 (65.1%) |
| Unknown | 8 (7.5%) |
| BCL2 expression | |
| Negative | 24 (24.2%) |
| Positive | 75 (75.8%) |
| BCL6 expression | |
| Negative | 6 (7.0%) |
| Positive | 80 (93.0%) |
| CD10 expression | |
| Negative | 32 (30.8%) |
| Positive | 72 (69.2%) |
| MUM1 expression | |
| Negative | 24 (28.2%) |
| Positive | 61 (71.8%) |
| Ki-67 expression | |
| < 90% | 68 (72.3%) |
| > 90% | 26 (27.7%) |
| MYC expression | |
| < 40% | 41 (70.7%) |
| > 40% | 17 (29.3%) |
| Cell of origin | |
| ABC | 62 (60.8%) |
| GCB | 40 (39.2%) |
| BCL2 rearrangement | |
| Negative/unknown | 87 (82.1%) |
| Positive | 19 (17.9%) |
| BCL6 rearrangement | |
| Negative/unknown | 90 (84.9%) |
| Positive | 16 (15.1%) |
| MYC rearrangement | |
| Negative/unknown | 101 (95.3%) |
| Positive | 5 (4.7%) |
| BCL6 and/or MYC rearrangement | |
| Negative/unknown | 85 (80.2%) |
| Positive | 21 (19.8%) |
| Double-hit | |
| Negative/unknown | 103 (97.2%) |
| Positive | 3 (2.8%) |
Abbreviations: LDH, lactate dehydrogenase; DLBCL, diffuse large B-cell lymphoma; ABC, activated B-cell-like; GCB, germinal centre B-cell-like.
*Parameters with unknown data include bone marrow involvement (n = 6), immunohistochemical expression for BCL2 (n = 17), BCL6 (n = 20), CD10 (n = 2), MUM1 (n = 21), Ki-67 (n = 12) and MYC (n = 48), as well as genomic rearrangement for BCL2 (n = 55), BCL6 (n = 53), and MYC (n = 56).